surmount-1 tirzepatide non-diabetic obesity weight loss SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, 𝗠𝗼𝘀𝘁 𝗽𝗲𝗼𝗽𝗹𝗲 𝗮𝘀𝘀𝘂𝗺𝗲 𝘁𝗵𝗲 𝘄𝗲𝗶𝗴𝗵𝘁

H.ChingaF.et al (2015)

52% of the semaglutide-treated test subjects achieved a weight loss response of greater than 5%, while a weight loss response of greater than 10% was achieved by 21% of the test subjects treated with the peptide

People plateau on semaglutide and want the greater weight loss potential of tirzepatide

Although metformin is a common drug for managing DM, however, monotherapy treatment with any antidiabetic drug will necessitate dosage increment since type 2 DM (T2DM) deteriorates over time due to the increasing pancreatic -cell dysfunction and will eventually require a combination therapy approach with another antidiabetic medication

Drinking water isn't the only way to maintain your hydration

The bigger issue is uncertainty